Humanwell Healthcare wins approval for two key drug products

Humanwell Healthcare Group announced the receipt of drug registration certificates for two key products, flurbiprofen axetil injection and levonorgestrel tablets.

Its subsidiary, Yichang Humanwell Pharmaceutical, obtained approval for flurbiprofen axetil injection, a non-steroidal anti-inflammatory drug for post-operative and cancer pain, with R&D investment totaling approximately 35 million yuan. The injection's 2024 national sales were approximately 980 million yuan.

Additionally, Wuhan Jiulong Humanwell Pharmaceutical, a subsidiary indirectly owned by Humanwell Healthcare Group, received approval for levonorgestrel tablets. These tablets are indicated for female emergency contraception, with R&D investment reaching approximately 13.5 million yuan. National sales for levonorgestrel tablets in 2024 were about 114 million yuan.

These approvals grant Humanwell Healthcare the right to market these drugs domestically, expanding its product pipeline and expected to positively impact the company’s performance. The company will proceed with manufacturing and market launch based on demand, while cautioning investors about potential risks from industry policies and market conditions.